Tổng quan thuốc chống đông đường uống thế hệ mới

Authors

  • Huy Nguyễn Bửu
  • Anh Nguyễn Hiền Việt
  • Điệp Nguyễn Thị Hồng
  • Nhựt Nguyễn Ánh
  • Cẩm Thái Thị

Keywords:

anticoagulation drug, vitamin K antagonist, dabigatran, rivaroxaban, apixaban, thrombosis, serious bleeding

Abstract

Vitamin K antogonist drug is used for patients with high risk of thrombosis, by preventing the blood clots that trigger heart attack and stroke, the anticoagulant drug warfarin, acenocoumarol saves countless lives. The anticoagulation drug is used after treating with heparin. Doctors must regularly monitor patients’ blood levels in order to prescribe a high enough dose of warfarin to prevent deadly blood clots, but not an excessive dose that could lead to fatal hemorrhage. Recently, new antithrombotic drugs that act directly by inhibiting activated coagulation factors such as factor X or thrombin have been developed and investigated in phase III clinical trials to offer the prevention and treatment venous thromboembolism and anticoagulant therapy management will be most probably improved in the coming years.

Author Biography

Cẩm Thái Thị

Thạc sĩ Trường Đại học Nam Cần Thơ

Published

2019-07-01

How to Cite

Nguyễn Bửu, H., Nguyễn Hiền Việt, . A., Nguyễn Thị Hồng, Điệp, Nguyễn Ánh, N., & Thái Thị, C. (2019). Tổng quan thuốc chống đông đường uống thế hệ mới. Journal of Science and Development Economics, (5+6), 13–24. Retrieved from https://jsde.nctu.edu.vn/index.php/jsde/article/view/23